 Home > Medical News > Latest Medical News > Merck's oral new crown drug molnupiravir approved

Merck's oral new crown drug molnupiravir approved

 Last Update: 2021-12-09
 Source: Internet
 Author: User

Tags

parkinson's treatment drug

crown

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

According to reports, the British Medicines and Health Products Regulatory Agency (MHRA) has approved the new crown oral drug molnupiravir developed by (MRK.

On November 4, Merck/Ridgeback announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing of molnupiravir (MK-4482, EIDD-2801) in the UK for the treatment of severe and mild to moderate COVID with a higher risk of hospitalization -19 adult patients

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Merck's new crown oral drug Molnupiravir emergency authorization application approved

01-12

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Merck's oral new crown drug molnupiravir approved

Related Articles

Merck's new crown oral drug Molnupiravir emergency authorization application approved